Aiming to plug a gap in the marketplace

Altacor, an ophthalmic specialty pharmaceutical company, has announced an addition to its dry eye product portfolio – Comfortear Lacrisolve 180 Absorbable Punctum Plugs.

Lacrisolve plugs provide predictable occlusion therapy lasting up to 180 days, almost double the duration of most other absorbable plugs, according to the company.

The new plugs are intended to temporarily treat the symptoms of dry eye disease, including post-surgery, as well as contact lens intolerance secondary to dry eye disease, and to increase efficacy of ocular medications and lubricants.

Made from an innovative polymer material called polydioxanone, the plugs have been designed with precision and made for comfort, Altacor highlights.

Available in two sizes, 0.4mm and 0.5mm, the implants are supplied sterile, with two plugs provided per pack.

They are aimed at specialist opticians with an interest in dry eye and consultant ophthalmologists in hospitals.

Comfortear Lacrisolve 180 Plugs are said by Altacor to be an ideal addition to a healthcare professional’s toolkit for when patients need more than drops to treat dry eye.

The plugs are effective in the horizontal canaliculi, are comfortable after proper placement and will not fall out of the punctum. Punctal dilation and topical anaesthesia are not typically required for the insertion of the plugs, the company emphasises.

For more information, visit the Altacor website.